MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
13.29
-0.60
-4.29%
After Hours: 13.65 +0.37 +2.75% 18:49 05/15 EDT
OPEN
13.54
PREV CLOSE
13.88
HIGH
13.90
LOW
13.17
VOLUME
998.05K
TURNOVER
--
52 WEEK HIGH
18.61
52 WEEK LOW
4.200
MARKET CAP
1.48B
P/E (TTM)
-8.8173
1D
5D
1M
3M
1Y
5Y
1D
LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 6h ago
A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Recent Share Price Volatility
Simply Wall St · 9h ago
Amylyx announces publication of Phase 2 open-label HELIOS trial data
TipRanks · 1d ago
Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome; Results Demonstrate Continued Improvements In Pancreatic Beta Cell Function Through Week 48
Benzinga · 1d ago
Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome
PUBT · 1d ago
AMYLYX PHARMACEUTICALS ANNOUNCES PEER-REVIEWED PUBLICATION OF PHASE 2 OPEN-LABEL HELIOS TRIAL DATA FOR AMX0035 IN THE JOURNAL OF CLINICAL INVESTIGATION
Reuters · 1d ago
Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?
Simply Wall St · 5d ago
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate)
Seeking Alpha · 5d ago
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.